Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Christmas Comes Early
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Jefferies Maintains a 'Buy' on Forest Laboratories (FRX); Quickly Moving Into Pole Position
August 31, 2012 7:49 AM EDTJefferies maintains a 'Buy' on Forest Laboratories (NYSE: FRX) price target of $41.00.
Analyst, Corey Davis, said, "With yet another big win for Forest's (and partner Ironwood's (Nasdaq: IRWD)) R&D team, linaclotide (new brand name Linzess)... More
Cantor Fitzgerald Reiterates a 'Sell' on Ironwood Pharmaceuticals (IRWD); Shares Still Overvalued
August 31, 2012 7:33 AM EDTCantor Fitzgerald reiterates a 'Sell' on Ironwood Pharmaceuticals (NASDAQ: IRWD) price target of $8.00.
Analyst, Irina Rivkind, said, "We already incorporated assumptions for 2012 Linzess (linaclotide) approval in our numbers for both Ironwood and partner Forest (assume load-in revenues of $10M for 4Q:12). We do model... More
FDA Approves IBS-C Treatment Linzess (IRWD) (FRX)
August 30, 2012 11:05 AM EDTBelow is the FDA press release related to approval of Ironwood Pharmaceuticals' (NASDAQ: IRWD) and Forest Labs' (NYSE: FRX) Linzess:
Press Release:
The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.
According to the National Institutes of Health, an estimated 63 million people are affected by chronic constipation. Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and do not respond to standard... More
